FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
PBS5d
The FDA banned Red 3 food coloring. A scientist explains the dye’s history and health risks
Over 35 years after the first study linking the artificial food dye Red 3 to thyroid cancer in rats was published, the U.S.
Food and Drug Administration wants to put nutrition labels front and center on food products
The U.S. Food and Drug Administration wants to put nutrition information front and center on food products to give consumers ...
FDA approves new type of non-opioid pain medication
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
US FDA approves Axsome Therapeutics' migraine drug
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
FDA Approves the First Non-Opioid Pain Drug in 20 Years
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...
FDA approves new type of nonopioid painkiller for acute pain
The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.
FDA approves new painkiller designed to avoid opioid addiction risk
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
WHDH1h
FDA approves first new type of pain medication in 25 years
The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than ...
WNYT NewsChannel 132h
FDA approves new nonopioid painkiller for acute pain
On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...
BioPharma Dive15h
Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...